Related Experiment Video
Updated: Feb 9, 2026

Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease
Published on: August 24, 2019
Improving the prescribing of palivizumab
Simone Trist1,2, Emily Horsley1,2, Hala Katf1,2
1Sydney Children's Hospital Network, Sydney, New South Wales, Australia.
Insights
Palivizumab use in high-risk children for respiratory syncytial virus (RSV) often deviates from guidelines. A streamlined process improved adherence but requires further refinement for optimal effectiveness in preventing severe RSV disease.
Area of Science:
- Pediatrics
- Infectious Diseases
- Pharmacology
Background:
- Palivizumab is a monoclonal antibody used to prevent respiratory syncytial virus (RSV) in high-risk children.
- Suboptimal prescribing and adherence to guidelines for palivizumab have been reported.
- Evaluating palivizumab utilization in Australian pediatric hospitals is crucial for improving patient outcomes.
Purpose of the Study:
- To review the utilization and effectiveness of palivizumab in two tertiary pediatric hospitals.
- To assess the impact of a streamlined individual patient use (IPU) pro forma on palivizumab prescribing practices.
- To identify areas for improvement in palivizumab administration and adherence to best-practice guidelines.
Main Methods:
- Retrospective review of children prescribed palivizumab between January 2013 and December 2014.
- Comparison with children admitted to pediatric intensive care units (PICUs) with RSV infection.
- Implementation and review of a streamlined IPU pro forma at one hospital in 2015.
Main Results:
- Prior to the intervention, 32% of palivizumab recipients at one hospital did not meet guidelines, and 32% did not complete the course.
- None of the eligible children admitted to PICU for RSV received palivizumab prior to admission.
- After the streamlined IPU implementation, 27% of recipients still did not meet guidelines, and 63% did not complete the course.
Conclusions:
- Palivizumab is frequently prescribed without adherence to best-practice guidelines, and eligible patients may not receive it.
- The streamlined IPU pro forma showed potential but requires further refinement to improve guideline adherence and completion rates.
- Complementary strategies are needed to enhance compliance and optimize palivizumab's effectiveness in preventing severe RSV disease.
Aim:
Palivizumab prevents respiratory syncytial virus (RSV) in children at high risk of severe disease. This paper reviews the use and effectiveness of palivizumab at two tertiary paediatric hospitals (hospitals A and B) in New South Wales, Australia.
Methods:
Children prescribed palivizumab during the pre-intervention period, 1 January 2013 until 31 December 2014, were compared with children under 2 years of age who were admitted to paediatric intensive care units (PICUs) with an RSV infection. Eligibility for palivizumab was determined. To improve evidence-based utilisation of palivizumab, a 'streamlined palivizumab individual patient use' (IPU) pro forma was introduced at hospital A during 2015, and its applicability was reviewed.
Results:
In the 2 years prior to implementing the streamlined IPU, 47 children received palivizumab, with 87% at hospital A. Of the children at hospital A, 32% did not meet the guidelines, and 32% did not complete the course. While 13% of children admitted to PICU for RSV infection were eligible for palivizumab, none received it prior to admission. In 2015, 16 streamlined IPUs were submitted, and 11 patients received palivizumab. Of these patients, 27% did not meet the guidelines, and 63% did not complete the course. Of the children who received palivizumab during the three RSV seasons, one developed an RSV infection, and none were admitted to PICU.
Conclusions:
Palivizumab is often prescribed without meeting recognised best practice guidelines, and patients eligible are frequently not prescribed palivizumab. The streamlined IPU, implemented in hospital A, excluded patients who did not meet guidelines. The pro forma needs further refinement, and complementary strategies introduced to improve compliance.
Related Concept Videos
Improving Translational Accuracy
Improving Translational Accuracy
Confirmation Biases
Altruism
Nature and Nurture
Biodiversity and Human Values

